12,352.35-3.15
Stock Analysis, IPO, Mutual Funds, Bonds & More

USFDA recommends action against Strides Pharma Science Puducherry unit

The company believes that the classification will not have an impact on the current supplies and revenues from the facility," Strides Pharma said.

PTI|
May 06, 2019, 01.50 PM IST
0Comments
Getty Images
Pharma 1 - Getty
According to the USFDA, an OAI means regulatory and/or administrative actions will be recommended for the facility which was inspected after it determines if the areas evaluated were in compliance with applicable laws and regulations.
Strides Pharma Science Ltd Monday said the US health regulator has classified its Puducherry facility as official action initiated (OAI) for non-compliance of norms following an inspection. The company has received a communication from the US Food and Drug Administration (USFDA) on May 4, 2019, classifying the facility as OAI based on the inspection conducted from January 28 to February 5, 2019, Strides Pharma Science said in a regulatory filing.

According to the USFDA, an OAI means regulatory and/or administrative actions will be recommended for the facility which was inspected after it determines if the areas evaluated were in compliance with applicable laws and regulations.

"While the company is disappointed with the outcome of the inspection, the company believes that the classification will not have an impact on the current supplies and revenues from the facility," Strides Pharma Sciences said.

It, however, said of the 34 ANDA's (abbreviated new drug application) pending approval, Puducherry has 10 ANDA's where the company expects delays until the facility is reclassified.

Also Read

Kasol, Puducherry & Gokarna: Visit these offbeat year-ender getaways

Indian Coast Guard to set up helicopter base in Puducherry

Tamil Nadu, Puducherry likely to receive heavy rainfall today: IMD

A day before release, Cong govts in Puducherry, MP & Chhattisgarh declare 'Chhapaak' tax-free

SC to hear in July Puducherry LG-CM row

Comments
Add Your Comments
Commenting feature is disabled in your country/region.

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service